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Background
The manufacture of a majority of clinical T cell products
for immunotherapy applications requires ex vivo T cell
culture and expansion. Commercialization of T cell man-
ufacturing processes requires reagents that meet regula-
tory guidelines and ultimately help reduce manufacturing
cost of goods. A key component in many T cell culture
protocols is human serum, which is expensive and may
require testing prior to use for the manufacture of a
cGMP-compliant T cell product. To this end, we have
developed a xeno-free serum replacement supplement
with defined components that can be used in combina-
tion with several different cell culture media to support
ex vivo expansion of T cells.
Results
T cells activated ex vivo and expanded with Dynabeads®
CD3/CD28 CTSTM and cultured in OpTmizer™
CTS™, X-VivoTM 15, or AIM-V® CTS™ supplemented
with pooled human serum or serum free T cell serum
replacement showed similar growth kinetics, total fold
expansion and transduction efficiency after 2 weeks in
culture. Numbers of expanded CD4+ and CD8+ T cells
were comparable in the expanded cultures regardless in
the presence of human serum or the newly developed
SRS-XF. Restimulated T cells expanded in serum free
T cell serum replacement show similar cytokine profile
and proliferation as T cells expanded in human serum.
Conclusion
This study shows that human serum may be replaced by
a xeno-free formulation in several commonly used cell
culture media to support ex vivo expansion and lentiviral
transduction of polyclonal T cells. Culturing T cells
in serum free T cell serum replacement facilitates a
favourable culture profile and immune function. The
serum free T cell serum replacement contains only fully
tested human-derived or human recombinant proteins
which facilitates supply security for clinical large scale and
commercial therapies.
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